Acquisition of NZP

Archer Capital today completed the acquisition of a majority shareholding in New Zealand Pharmaceuticals (“NZP”) from New Zealand based Direct Capital and other shareholders. NZP manufactures pharmaceutical intermediaries and diagnostic products for pharmaceutical and biotechnology companies around the world. Archer Capital is one of Australia’s and New Zealand’s leading private equity firms with $2 billion in funds under management and a twenty year track record of successfully partnering with the management teams of New Zealand and Australian companies. Previous Archer Capital investments in New Zealand include Hirequip, OneSource, BJ Ball Papers and the Aspire2 Group. The strategy and direction of the business will continue to be the same, with Archer Capital partnering with the existing management team for the next phase of growth. A large number of employees including CEO Andy Lewis, and the Senior Management Team have invested alongside Archer, together with long standing Directors of NZP Richard Garland, Barry Old and Graeme Milne who will all be remaining on the Board and retaining a significant investment in the business. Archer plans to invest in NZP to enable it to continue its strong growth of recent years and to capitalise on its recent advances in its bile acid chemistry programme spearheaded by the business’s world-leading R&D team. For further information: